In summary, these data may suggest that valproate recruits EZH2 to the CD20 promoter in del13q/NOTCHwt CLL patients during initial treatment, but that this effect is lost upon repeated valproate-exposure. The gene discussed is EZH2; the disease is B-cell chronic lymphocytic leukemia.